SEP-479 oral small-molecule agonist of the parathyroid hormone 1 receptor (PTH1R) aimed at treating hypoparathyroidism Recent Highlights: In May 2025, Septerna signed an exclusive global collaboration with Novo Nordisk worth up to $2.2B to co-develop oral small molecule GLP-1, GIP, and glucagon receptor agonists
Patients should maintain regular contact with their healthcare provider during this initial period to address concerns, adjust lifestyle strategies, and ensure appropriate progression through the dose escalation schedule
The mean percentage of body weight loss at 72 weeks was 15.0% at the lowest dose, and 20.9% in the highest dose cohort (compared to 3.1% in placebo) (NCT04184622)
Constantinescu, A., Pick, U., Handelman, G
Below are additional answers covering more specific details about the downsides of Ipamorelin, along with other common peptide concerns